|
|
||||||||||||||
|
|
|||||||||||||||
Therapeutics |
GP/FP/Primary care






IM/Internal medicine 





Allergy 





Respirology 





Immunology 





Key Words: asthma desensitisation (immunologic)
| The first 150 words of the full text of this article appear below. |
METHODS
Data sources:
Medline (1966 to December 2001), the Cochrane Airways Group trials register (up to June 2001), EMBASE/Excerpta Medica, CINAHL, Current Contents, abstracts of dissertations, and reference lists.
Study selection and assessment:
studies in any language were selected if they were randomised controlled trials (RCTs) comparing AS immunotherapy with placebo, antigenically inactive controls, untreated controls, or inhaled steroids; or comparing house dust extract with placebo. Studies were assessed for methodological quality using the Jadad scale.
Outcomes:
asthma symptoms, medication requirements, lung function (including peak expiratory flow rate, FEV1, and thoracic gas volume), non-specific BHR (to histamine or methacholine), and AS BHR.
MAIN RESULTS
75 RCTs met the selection criteria (n = 3506). Patients who received AS immunotherapy (particularly mite, pollen, and animal dander allergens) had greater symptomatic improvement, had reduced asthma medication requirements, and were less likely to develop increased non-specific or AS BHR than those who received placebo (table![]()
Bernard R Adelsberg, MD
Hamden Internal Medicine Associates
Hamden, Connecticut, USA
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |